ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Alnylam is a pioneering biopharmaceutical company focused on discovering, developing, and commercializing medicines based on RNA interference, a Nobel Prize-winning mechanism that silences disease-causing genes. Founded in 2002, the company pioneered clinical applications of small interfering RNA (siRNA) and has become the leading practitioner of what it calls RNAi therapeutics—a fundamentally different approach to drugging targets once considered beyond reach with traditional small-molecule chemistry or biologics.

The company’s early focus on rare genetic diseases proved transformative. Its lead program, patisiran, treats transthyretin amyloidosis, a severe rare disorder where abnormal protein accumulation damages nerves and the heart. The drug’s approval marked the first FDA green light for an intravenous RNAi therapeutic and became a proof-of-concept that the technology could work in humans at scale. Givosiran followed, addressing acute intermittent porphyria, another ultra-rare genetic disorder with no other effective options. These landmark approvals validated a decade of development and gave Alnylam a foothold in a market where the unmet medical need commands premium pricing and strong patient advocacy.

Alnylam now operates across multiple therapeutic areas, extending beyond rare disease. The company’s pipeline spans cardiovascular disease, metabolic disorders, and other segments where selective gene silencing offers an advantage. A particularly high-stakes program targets transthyretin in cardiac amyloidosis—a broader patient population than the inherited form—where demand and competition remain substantial. The company has also pursued partnerships and licensing deals to accelerate development and diversify its revenue streams, reflecting the capital intensity and execution risk of bringing RNAi drugs to market.

Below is how Alnylam organizes its therapeutic focus:

The company’s business model hinges on sustained execution: translating the RNAi concept into approved, marketed drugs; defending intellectual property around target selection and formulation; and expanding into larger populations where affordability and reimbursement become critical. Manufacturing scale-up and the economics of gene-silencing therapeutics—which often require intravenous dosing or special delivery mechanisms—remain ongoing challenges. Competition in the space is intensifying as other biotechs and large pharma companies invest in RNAi and competing modalities like gene therapy and antisense oligonucleotides. Alnylam’s early-mover status and depth of clinical data provide a moat, but long-term success depends on pipeline breadth, real-world efficacy in larger populations, and the company’s ability to fund development without major acquisition or partnership.

As a public company, Alnylam trades on the NASDAQ, and investors can review therapeutic priorities and financial performance in its 10-K filings, which detail segment revenue, R&D spending, and clinical trial status.